

# Pradaxa® (dabigatran etexilate)

## PRESCRIBER GUIDE

The recommendations only refer to the indication

- primary VTE prevention with once daily dosing

This guide provides recommendations for the use of PRADAXA® in order to minimize the risk of bleeding

- Indication
- Contraindications
- Perioperative management
- Dosing
- Special patient populations potentially at higher risk of bleeding
- Coagulation tests and their interpretation
- Overdose
- Management of bleeding complications
- PRADAXA® Patient Alert Card and counseling

This prescriber guide does not substitute the PRADAXA® Summary of Product Characteristics (SmPC)<sup>1</sup>.





# INDICATIONS

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp).

Indications  
& Contraindication



# CONTRAINDICATION



CONTRAINDICATION

- Hypersensitivity to the active substance or to any of the excipients
- Severe renal impairment ( $\text{CrCL} < 30 \text{ mL/min}$ )
- Active clinically significant bleeding
- Lesion or condition, if considered a significant risk factor for major bleeding. This may include:
  - current or recent gastrointestinal ulceration
  - presence of malignant neoplasms at high risk of bleeding
  - recent brain or spinal injury
  - recent brain, spinal or ophthalmic surgery
  - recent intracranial haemorrhage
  - known or suspected oesophageal varices
  - arteriovenous malformations
  - vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
- Concomitant treatment with any other anticoagulant agent e.g.
  - unfractionated heparin (UFH)
  - low molecular weight heparins (enoxaparin, dalteparin etc.)
  - heparin derivatives (fondaparinux etc.)
  - oral anticoagulants (warfarin, rivaroxaban, apixaban etc.) except under specific circumstances. These are switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation.
- Hepatic impairment or liver disease expected to have any impact on survival
- Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole, cyclosporine, itraconazole, dronedarone and the fixed-dose combination glecaprevir/ pibrentasvir
- Prosthetic heart valves requiring anticoagulant treatment

# DOSING

## DOSING<sup>1</sup>

Dosing in primary VTE prevention after total hip or total knee surgery

RECOMMENDED DAILY DOSE TAKEN AS  
2 CAPSULES OF 110 MG ONCE DAILY<sup>2,3</sup>



	Treatment initiation on day of surgery 1–4 hours after completed surgery	Maintenance dose starting on the first day after surgery	Duration of maintenance dose
Patients following elective knee replacement surgery	Single capsule of 110 mg PRADAXA®	220 mg PRADAXA® once daily taken as 2 capsules of 110 mg	10 days
Patients following elective hip replacement surgery			28–35 days

**Please note:** If haemostasis in the post-operative phase is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery, then treatment should be initiated with 2 capsules once daily.

## DOSING REDUCTION

Dosing in primary VTE prevention after total hip or total knee surgery

### LOWER DAILY DOSE FOR SPECIAL POPULATIONS TAKEN AS 2 CAPSULES OF 75 MG ONCE DAILY<sup>1,2</sup>



	Treatment initiation on day of surgery 1-4 hours after completed surgery	Maintenance dose starting on the first day after surgery	Duration of maintenance dose
Patients with moderate renal impairment (creatinine clearance (CrCL) 30–50 mL/min)	Single capsule of 75 mg dabigatran	150 mg dabigatran once daily taken as 2 capsules of 75 mg	10 days (knee replacement surgery) or 28–35 days (hip replacement surgery)
Patients who receive concomitant verapamil, amiodarone, quinidine			
Patients aged 75 or above			

In patients with both moderate renal impairment and concomitantly treated with verapamil, a dose reduction of dabigatran to 75 mg once daily should be considered.



### RECOMMENDATION FOR KIDNEY FUNCTION MEASUREMENT IN ALL PATIENTS

- Renal function should be assessed by calculating the **creatinine clearance (CrCL)** by the Cockcroft-Gault\* method **prior to initiation of treatment with PRADAXA®** to exclude patients with severe renal impairment (i.e. CrCL <30 mL/min)
- Renal function should also be assessed when a decline in renal function is suspected **during treatment** (e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products)

#### \*Cockcroft-Gault formula

For creatinine in mg/dL

$$\frac{(140 - \text{age [years]}) \times \text{weight [kg]} (\times 0.85 \text{ if female})}{72 \times \text{serum creatinine [mg/dL]}}$$

For creatinine in µmol/L

$$\frac{1.23 \times (140 - \text{age [years]}) \times \text{weight [kg]} (\times 0.85 \text{ if female})}{\text{serum creatinine [µmol/L]}}$$

# SWITCHING

## PRADAXA® treatment to parenteral anticoagulant

It is recommended to wait 24 hours after the last dose before switching from PRADAXA® to a parenteral anticoagulant

### Pradaxa treatment to parenteral anticoagulant

It is recommended to wait 24 hours after the last dose before switching from Pradaxa to a parenteral anticoagulant.



Last dose of  
Pradaxa



Wait 24 hrs



Start injectable  
anticoagulant  
and stop Pradaxa

SWITCHING

## Parenteral anticoagulants to PRADAXA®

The parenteral anticoagulant should be discontinued and PRADAXA® started 0-2 hours prior to the time that the next dose of the alternate therapy would be due, or at the time of discontinuation in case of continuous treatment (e.g. intravenous Unfractionated Heparin (UFH)).

### Parenteral anticoagulants to Pradaxa

Discontinue the parenteral anticoagulant and start Pradaxa 0-2 hours prior to the time that the next dose of the alternate therapy would be due, or at the time of discontinuation in case of continuous treatment (e.g. intravenous UFH).



Previous  
injectable  
anticoagulant



Start Pradaxa 0-2 hours  
before next dose of injectable  
anticoagulant is due



Do not give due  
dose of injectable  
anticoagulant



# METHOD OF ADMINISTRATION

PRADAXA® is for oral use.

- The capsules can be taken with or without food. PRADAXA® should be swallowed whole with a glass of water, to facilitate delivery to the stomach
- Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding

## Special patient populations potentially at higher risk of bleeding

Patients with an increased bleeding risk (see Table 1) should be closely monitored for signs or symptoms of bleeding or anaemia, especially if risk factors are combined. An unexplained fall in hemoglobin and/or hematocrit or blood pressure should lead to a search for a bleeding site. A coagulation test (see section Coagulation tests and their interpretation) may help to identify patients with an increased bleeding risk caused by excessive dabigatran exposure. When clinically relevant bleeding occurs, treatment should be interrupted.

For situations of life-threatening or uncontrolled bleeding, when rapid reversal of the anticoagulation effect of dabigatran is required reversal agent can be used.<sup>9</sup>

Table 1: Risk factors which may increase the haemorrhagic risk\*

Pharmacodynamic and kinetic factors	<ul style="list-style-type: none"> <li>• Age <math>\geq 75</math> years</li> </ul>
Factors increasing dabigatran plasma levels	<p>Major:</p> <ul style="list-style-type: none"> <li>• Moderate renal impairment (30-50 mL/min CrCL)<sup>†</sup></li> <li>• Strong P-gp<sup>†</sup> inhibitor comedication (see section Contraindication)</li> <li>• Mild to moderate P gp inhibitor co medication (e.g. amiodarone, verapamil, quinidine and ticagrelor)</li> </ul> <p>Minor:</p> <ul style="list-style-type: none"> <li>• Low body weight (&lt;50 kg)</li> </ul>
Pharmacodynamic interactions	<ul style="list-style-type: none"> <li>• Acetylsalicylic acid and other platelet aggregation inhibitors such as clopidogrel</li> <li>• NSAID</li> <li>• SSRIs or SNRIs<sup>†</sup></li> <li>• Other medicinal products which may impair haemostasis</li> </ul>
Diseases/procedures with special haemorrhagic risks	<ul style="list-style-type: none"> <li>• Congenital or acquired coagulation disorders</li> <li>• Thrombocytopenia or functional platelet defects</li> <li>• Esophagitis, gastritis, gastroesophageal reflux</li> <li>• Recent biopsy, major trauma</li> <li>• Bacterial endocarditis</li> </ul>

\* For special patient populations requiring a reduced dose, see section Dosing.

<sup>†</sup> CrCL: Creatinine clearance; P-gp: P-glycoprotein; ICH: intracranial hemorrhage; SSRIs: selective serotonin re-uptake inhibitors; SNRIs: serotonin norepinephrine re-uptake inhibitors.



## PERIOPERATIVE MANAGEMENT

### Surgery and interventions

Patients on PRADAXA® who undergo surgery or invasive procedures are at increased risk of bleeding. Therefore, surgical interventions may require the temporary discontinuation of PRADAXA®. Clearance of dabigatran in patients with renal insufficiency may take longer. This should be considered in advance of any procedures.

### Emergency surgery or urgent procedures

PRADAXA® should be temporarily discontinued. When rapid reversal of the anticoagulation effect of dabigatran is required the specific reversal agent (idarucizumab) to PRADAXA® can be used.<sup>9</sup> Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. PRADAXA® treatment can be re-initiated 24 hours after administration of (idarucizumab), if the patient is clinically stable and adequate haemostasis has been achieved.

### Subacute surgery/interventions

PRADAXA® should be temporarily discontinued. A surgery/intervention should be delayed if possible until at least 12 hours after the last dose. If surgery cannot be delayed the risk of bleeding may be increased. This risk of bleeding should be weighed against the urgency of intervention.

### Elective surgery

If possible, PRADAXA® should be discontinued at least 24 hours before invasive or surgical procedures. In patients at higher risk of bleeding or in major surgery where complete haemostasis may be required consider stopping PRADAXA® 2–4 days before surgery. For discontinuation rules see Table 2.

**Table 2: Discontinuation rules before invasive or surgical procedures**

Renal function (CrCL mL/min)	Estimated half-life (hours)	Stop PRADAXA® before elective surgery	
		High risk of bleeding or major surgery	Standard risk
≥80	~13	2 days before	24 hours before
≥50 – <80	~15	2–3 days before	1–2 days before
≥30 – <50	~18	4 days before	2–3 days before (>48 hours)



### Spinal anaesthesia/epidural anaesthesia/lumbar puncture

The risk of spinal or epidural haematoma may be increased in cases of traumatic or repeated puncture and by the prolonged use of epidural catheters. After removal of a catheter, an interval of at least 2 hours should elapse before the administration of the first dose of PRADAXA®. These patients require frequent observation for neurological signs and symptoms of spinal or epidural haematoma.



### COAGULATION TESTS AND THEIR INTERPRETATION

PRADAXA® treatment does not need routine clinical monitoring<sup>3,4</sup>.

In cases of suspected overdose or in patients treated with PRADAXA® presenting in emergency departments or prior to surgery, it may be advisable to assess the anticoagulation status.

- **International Normalised Ratio (INR)**

The INR test is unreliable in patients on PRADAXA® and should not be performed.

- **Activated Partial Thromboplastin Time (aPTT)**

The aPTT test provides an approximate indication of the anticoagulation status but is not suitable for precise quantification of anticoagulant effect.

- **Dilute Thrombin Time (dTT), Thrombin Time (TT), Ecarin Clotting Time (ECT)**

There is a close correlation between plasma dabigatran concentration and degree of anticoagulant effect<sup>1,2</sup>. For a quantitative measurement of dabigatran plasma concentrations, several dabigatran calibrated assays based on dTT have been developed<sup>5-8</sup>. A plasma level of > 67 ng/mL dabigatran plasma concentration prior to the next medicinal product intake may be associated with a higher risk of bleeding<sup>1</sup>. A normal dTT measurement indicates no clinically relevant anticoagulant effect of dabigatran. TT and ECT may provide useful information, but the tests are not standardized.



## PERIOPERATIVE MANAGEMENT

**Table 3: Coagulation test thresholds at trough (i.e. prior to the next medicinal product intake) that may be associated with an increased risk of bleeding. Please note: in the first 2–3 days after surgery, false prolonged measures may be detected.<sup>2,3</sup>**

Test (trough value)	
dTT [ng/mL]	> 67
ECT [x-fold upper limit of normal]	No data*
aPTT [x-fold upper limit of normal]	> 1.3
INR	Should not be performed

\* The ECT was not measured in patients treated for prevention of VTEs after hip or knee replacement surgery with 220 mg PRADAXA® once daily.

**Time point:** Anticoagulant parameters depend on the time when the blood sample was taken as well as when the last dose was given. A blood sample taken 2 hours after PRADAXA® ingestion (peak level) will have different (higher) results in all clotting tests compared with a blood sample taken 20–28 hours (trough level) after ingestion of the same dose.

## OVERDOSE<sup>1-2</sup>

In case of an overdose suspicion, coagulation tests may help to assess the coagulation status. Excessive anticoagulation may require interruption of PRADAXA®. Since dabigatran is excreted predominantly by the renal route, adequate diuresis must be maintained. As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies. PRADAXA® overdose may lead to haemorrhage. In the event of hemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. (see section Management of bleeding complications). General supportive measures such as application of oral activated charcoal may be considered to reduce absorption of dabigatran.

## PRADAXA® Patient Alert Card and counseling

A Patient alert card is provided to your patient. The patient should be instructed to carry the Patient alert card at all times and present it when seeing a health care provider. The patient should be counseled about the need for compliance and signs of bleeding and when to seek medical attention.

## MANAGEMENT OF BLEEDING COMPLICATIONS<sup>1,2,9</sup>

For situations when rapid reversal of the anticoagulant effect of dabigatran is required (life-threatening or uncontrolled bleeding or for emergency surgery/urgent procedures) the specific reversal agent (idarucizumab) can be used. Depending on the clinical situation appropriate standard treatment, e.g., surgical haemostasis and blood volume replacement, should be undertaken. Consideration may be given to the use of fresh whole blood, fresh frozen plasma and/or platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet medicinal products have been used. Coagulation factor concentrates (activated or non-activated) or recombinant Factor VIIa may be taken into account. However, clinical data are very limited.







*Experienced Protection*

#### References

1. PRADAXA® Summary of Product Characteristics. Boehringer Ingelheim.
2. van Ryn J et al. Thromb Haemost 2010; 103:1116–1127.
3. Liesenfeld K-H et al. Br J Clin Pharmacol 2006; 62:527–537.
4. Stangier J et al. Br J Clin Pharmacol 2007; 64:292–303.
5. Hemoclot® thrombin inhibitor assay (Hyphen BioMed, Neuville-sur-Oise, France).  
[www.clottingtesting.com](http://www.clottingtesting.com)
6. HemosIL® assay (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).  
[www.instrumentationlaboratory.com](http://www.instrumentationlaboratory.com)
7. Technoclott® DTI Dabigatran assay (Technoclone GmbH, Vienna, Austria).  
<http://www.technoclone.com/products/coagulation/control-plasma/dabigatran-cont>
8. INNOVANCE® DTI Assay (Siemens Healthineers GmbH, Erlangen, Germany)  
<https://www.healthcare.siemens.com/hemostasis>
9. Pollack C et al. NEJM 2015; 373: 511-20

PRADAXA® is a registered trademark of Boehringer Ingelheim Pharma GmbH and Co. KG and used under license.

Adverse events should be reported to Iraqi pharmacovigilance center on: [iaiphvc@yahoo.com](mailto:iaiphvc@yahoo.com), [iraqiphvc@moh.gov.iq](mailto:iraqiphvc@moh.gov.iq)  
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on: [PV\\_local\\_Egypt@boehringer-ingelheim.com](mailto:PV_local_Egypt@boehringer-ingelheim.com)



**Boehringer  
Ingelheim**

Baghdad, Iraq  
Hal AlWihda 52 – Sector 904 – Street 17 – House 231/  
E-Mail: [alshfapharma.info@alshfadrug.com](mailto:alshfapharma.info@alshfadrug.com)  
PV Address : Fax: +971 4 423 3638  
Phone: +2 (012) 7066 7262  
Email Address: [PV\\_local\\_Egypt@boehringer-ingelheim.com](mailto:PV_local_Egypt@boehringer-ingelheim.com)